Retinal Neurovascular Coupling in Patients Previously Infected With COVID-19

Launched by MEDICAL UNIVERSITY OF VIENNA · Dec 13, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how well the blood vessels in the eye respond after a person has been infected with COVID-19. Researchers want to compare the eye responses and blood flow between people who have had COVID-19, those experiencing long-term effects from the virus (often called long COVID), and healthy individuals who have never been infected. The goal is to gain a better understanding of how COVID-19 may impact eye health.

To participate, you need to be over 18 years old and a non-smoker. If you have had COVID-19, you should have had a positive test within the last six months and currently be free of the virus. Healthy participants must not have a history of COVID-19. Everyone will undergo eye exams to ensure their eye health is suitable for the study. Participants can expect to provide some medical history and undergo simple tests to measure eye function, contributing to important research that could help others affected by COVID-19.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Inclusion criteria for healthy subjects
• • Men and women aged over 18 years
• • Non-smokers
• • Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
• • No previous history of COVID-19 infection
• • Negative testing for SARS-CoV-2 seroprevalence using nucleocapsid antibody tests
• • Negative PCR test for SARS-CoV-2
• • Normal ophthalmic findings, ametropy \< 6 Dpt.
• • Inclusion criteria for subjects with history of COVID-19 infection
• • Men and women aged over 18 years
• • Non-smokers
• • History of COVID-19 infection (confirmed by a positive PCR test for SARS-CoV2 in the medical history) within the last 6 months
• • Positive testing for SARS-CoV-2 seroprevalence using spike protein IgG antibody tests
• • Negative PCR test for SARS-CoV-2
• • Inclusion criteria for subjects with long COVID-19
• • Men and women aged over 18 years
• • Non-smokers
• • History of COVID-19 infection (confirmed by a positive PCR test for SARS-CoV2 in the medical history)
• • Positive testing for SARS-CoV-2 seroprevalence
• • Negative PCR test for SARS-CoV-2
• • Long Covid according to the latest WHO-Guidelines
• Exclusion Criteria:
• Any of the following will exclude a healthy control subject from the study:
• • Symptoms of a clinically relevant illness in the 3 weeks before the first study day
• • Presence or history of a severe medical condition as judged by the clinical investigator
• • Participation in a clinical trial in the 3 weeks preceding the study
• • Blood donation during the previous three weeks
• • History or family history of epilepsy
• • Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
• • Best corrected visual acuity \< 0.8 Snellen
• • Pregnancy, planned pregnancy or lactatin
• • History of epilepsia
• Any of the following will exclude a subject with history of COVID-19 infection from the study:
• • Blood donation during the previous three weeks
• • History or family history of epilepsy
• • Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
• • Best corrected visual acuity \< 0.8 Snellen
• • Ametropy \>6 Dpt
• • Pregnancy, planned pregnancy or lactating
• • History of epilepsia
• Any of the following will exclude a subject with long COVID-19 from the study:
• • Blood donation during the previous three weeks
• • History or family history of epilepsy
• • Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
• • Best corrected visual acuity \< 0.8 Snellen
• • Ametropy \>6 Dpt
• • Pregnancy, planned pregnancy or lactating
• • History of epilepsia
• • Diabetes mellitus